HAT1 and lung cancer: When cells were treated with the apHAT610 aptamer at the stated concentration (2 × IC50), a statistically significant reduction in HAT1 activity, measured by histone H4 acetylation and HAT1 protein levels, was observed in lung cancer cell lines 24 h post-transfection.